INTERCEPT-T2D

Inflammation and the risk trajectory of complications in diabetics

Underway

23/01/2023

22/01/2026

Main objectives

The INTERCEPT-T2D project aims to establish whether a pro-inflammatory phenotypic profile contributes to the development of complications in type 2 diabetes (T2D), thus enabling the identification of patients most at risk of complications and the design of personalized preventive measures, using a large source of real-life data.

#AI | #Diabète | #EDS-APHP | #Europe

Challenge

In patients with type 2 diabetes, the rates of cardiovascular morbidity, chronic kidney disease, retinopathy, neuropathy and metabolic liver disease are still very high. Activation of inflammatory pathways is a known factor in these complications. Current antidiabetic treatments act as hypoglycemic agents without directly targeting inflammation, which has been shown to be a key factor in the development of the disease and its microvascular and macrovascular complications.

Methodology/Technology used

NLP, causal inference

Publications

Contacts

Louis Potier () & Gaël Varoquaux ()

Members

Consortium coordinated by INSERM, bringing together 12 partners, including AP-HP and Inria.

Useful links

https://intercept-t2d.eu/